Q3 2019 Earnings Call

Oh.

On the C.G.R.P. antibodies, and we're getting caught up in that isn't that a larger battle as well.

Thanks very much.

As a reminder, we are now conducting a question answer session if you'd like to ask a question. Please press start one on your telephone keypad.

Our next question is from David Sure Collie J.M.P. Securities. Please proceed with your question.

Yeah, Hi, this is actually going on for Dave just a quick one on F.S.S.F.S.S. shipments looks like they doubled again over the second quarter, what you'd just be able to give us any color on you know any approximate internal targets for this channel that you might have for the full year and then how should we think about contributions from this.

<unk> and you know how they could come into sales for 2020 and going forward from there. Thanks.

So I've got a very crazy forecasts, but I'm I'm not hearing any guidance with you just yet so keep asking.

As far as contribution.

We've got very healthy pricing under the S.S.S. contract and it's a very efficient channel and call point for US we're not we're not sharing the revenue with a lot of.

Distribution channel partners. So contribution is is very very.

Lucrative in that business model.

Got it just one more you mentioned that you know you ship to 48 of the V.A. treatment facilities can you just give us an idea of how many of these facilities exist in how quickly you feel you could reach a higher portion.

<unk>, so that there's there's roughly 160 campuses around the country.

That cover V.A.D. or military treatment facilities are both.

You know we've had sales you know book revenue from.

40 848 of them.

And we've got 10 reps in the field now so it's a reasonable number to cover maybe not all 160 of them, but we can get pretty good coverage.

Great. Thank you very much.

Our next question is from.

<unk>, who the Amir noble capital markets. Please proceed with your question.

Hello, again get for taking my question that my question will be you.

How about the current color light.

As well <unk>.

So.

We are.

We've created a lot of confusion about what we mean a bike covered lies.

And I think the.

The right number to give you today is 60 million covered lives of wage 20 million plus are covered it through the F.S.S. contract and another 30 million or so or cover to R.C.D.S. contract. That's previously been announced.

Okay.

[noise] or any updates on.

First data bank hold on to express.

Or I remember from spring mentioning prime tip, you didn't contract.

Update on.

No.

So yes, there are updates, but we have not announced anything publicly.

Okay. My my question will be a follow up well for my game prevention.

Okay, you want you wouldn't be required to get premium to data.

Prior to receiving day. Cleveland then you can get time mine would be for just have fun data from premium to range like what is the worst case scenario. If you are required to come back and complete Dan <unk> do you expect to see the data.

So I I think they're two separate.

Questions or issues were very confident that we can get the label extension based on.

The data and the responses that we have access to today.

The premium to study and I think we said this on the call. We we were about one third enrolled and we'd love to finish enrollment in the first half, but it may take a little bit longer to complete enrollment further into next year. So I don't have very Chris visibility on.

Current enrollment rates and and how long it projected that process.

Okay I have one more question, it's it's okay uh-huh.

It's been a reason I q.'s migrating Oh approval right well, how do they change Gamma course, oh position in the landscape does it do you think if any differently than you publish and treatment than it is going to do.

Some market share for that meet that approval.

I'm I'm not sure I understood. The questionnaires are you asking about one of the new drugs that's been approved correct yeah.

Indicate treats mountains.

Tony do you want to go ahead and feel that one sure I I don't think it really changes how we approach the.

Sales.

Pitch on <unk> acute setting it's not yet available on the market in fact, and you know we expect that they will be facing hurdles in terms of in terms of third party payer coverage because of the availability of generics in the front line acute.

<unk>.

I'm gonna or something you may shoes with the drug that you know in terms of.

Modify profile.

Okay. Thank you for thinking my question.

We have reached the end of the question answer session. Now, we're now trying to call back over to Dan Goldberger for closing remarks.

Alright, Thank you everybody for for joining our call and we look forward to providing our next update of the year round results.

I have a great evening by.

This conclude today's conference you may disconnect your lines at this time. Thank you for your participation.